Portage Biotech Inc. Common Stock (ATON) can sell. Click on Rating Page for detail.
The price of Portage Biotech Inc. Common Stock (ATON) is 11.01 and it was updated on 2025-10-08 13:00:18.
Currently Portage Biotech Inc. Common Stock (ATON) is in undervalued.
News |
---|
![]() AlphaTON Capital Corp Launches TON Digital Asset Treasury Strategy for the Telegram Ecosystem
|
![]() Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025
|
![]() Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements
|
![]() Portage Biotech and Compedica Stock-for-Stock Exchange
|
![]() Portage Biotech Stock Surges As It Prepares For Human Trial
|
StockPrice Release |
---|
News |
---|
Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7
|
Why Is Portage Biotech Stock Skyrocketing Friday?
|
Portage Biotech Shares More Than Double After Results of PORT-7 Tumor Treatment Trial
|
Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial
|
Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements
|
Portage Biotech Announces Completion of $2.15 Million Private Financing
|
Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company
|
Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter
|
Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024
|
Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives
|
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares
|
Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update
|
Portage Biotech Reports Business and Strategic Update
|
Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update
|